Dual proton pump inhibitor plus amoxicillin as an empiric anti-H. pylori therapy: Studies from the United States

Journal of Gastroenterology

Volumn 45, Issue 8, 2010, Pages 816-820

  Graham, David Y ^a   Javed, Syed Ussama ^a   Keihanian, Sara ^a   Abudayyeh, Suhaib ^a   Opekun, Antone R ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Amoxicillin; Clinical trial; H. pylori eradication; Helicobacter pylori; Proton pump inhibitors

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; CYP2C19 PROTEIN, HUMAN; OMEPRAZOLE; PROTON PUMP INHIBITOR; UNSPECIFIC MONOOXYGENASE;

ARTICLE; CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECT; FEMALE; GENETICS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGY; MIDDLE AGED; PH; PILOT STUDY; PROSPECTIVE STUDY; TREATMENT OUTCOME; UNITED STATES;

AMOXICILLIN; ANTI-BACTERIAL AGENTS; ARYL HYDROCARBON HYDROXYLASES; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; OMEPRAZOLE; PILOT PROJECTS; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; TREATMENT OUTCOME; UNITED STATES;

EID: 79952036201     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-010-0220-x     Document Type: Article

References (56)

1. Yamaoka Y, Graham DY, Lu H. Should triple therapy for Helicobacter pylori infection be abandoned as no longer effective? US Gastroenterol. 2008;4(1):65-7.
2. Huang AH, Sheu BS, Yang HB, Huang CC, Wu JJ, Lin XZ. Impact of Helicobacter pylori antimicrobial resistance on the outcome of 1-week lansoprazole-based triple therapy. J Formos Med Assoc. 2000;99(9):704-9.
3. Zanten SJ, Bradette M, Farley A, Leddin D, Lind T, Unge P, et al. The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. Aliment Pharmacol Ther. 1999;13(3):289-95. (Pubitemid 29142036)
4. Sheu BS, Wu JJ, Lo CY, Wu HW, Chen JH, Lin YS, et al. Impact of supplement with Lactobacillus- and bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2002;16(9):1669-75.
5. Bazzoli F, Pozzato P, Rokkas T. Helicobacter pylori: the challenge in therapy. Helicobacter. 2002;7(Suppl 1):43-9. (Pubitemid 35230814)
6. Georgopoulos SD, Ladas SD, Karatapanis S, Triantafyllou K, Spiliadi C, Mentis A, et al. Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line, Helicobacter pylori eradication therapies. Aliment Pharmacol Ther. 2002;16(3):569-75. (Pubitemid 34214538)
7. Peitz U, Sulliga M, Wolle K, Leodolter A, Von AU, Kahl S, et al. High rate of post-therapeutic resistance after failure of macrolidenitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study. Aliment Pharmacol Ther. 2002;16(2):315-24. (Pubitemid 34146373)
8. Vakil N, Lanza F, Schwartz H, Barth J. Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther. 2004;20(1):99-107. (Pubitemid 38938723)
9. Fuccio L, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med. 2007;147(8):553-62. (Pubitemid 351664506)
10. Zagari RM, Bianchi-Porro G, Fiocca R, Gasbarrini G, Roda E, Bazzoli F. Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study. Gut. 2007;56(4):475-9. (Pubitemid 46580501)
11. Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter. 2007;12(4):275-8. (Pubitemid 47196342)
12. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther. 2007;26(3):343-57. (Pubitemid 47063149)
13. Graham DY, Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol. 2008;5(321):331.
14. Graham DY, Lu H, Yamaoka Y. Therapy for Helicobacter pylori infection can be improved: sequential therapy and beyond. Drugs. 2008;68(6):725-36. (Pubitemid 351550527)
15. Unge P, Gad A, Gnarpe H, Olsson J. Does omeprazole improve antimicrobial therapy directed towards gastric Campylobacter pylori in patients with antral gastritis? A pilot study. Scand J Gastroenterol Suppl. 1989;167:49-54. (Pubitemid 19265491)
16. van der Hulst RW, Keller JJ, Rauws EA, Tytgat GN. Treatment of Helicobacter pylori infection: a review of the world literature. Helicobacter. 1996;1(1):6-19. (Pubitemid 126671070)
17. Bayerdorffer E, Miehlke S, Mannes GA, Sommer A, Hochter W, Weingart J, et al. Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. Gastroenterology. 1995;108:1412-7.
18. Bayerdörffer E, Mannes GA, Sommer A, Höchter W, Weingart J, Hatz R, et al. High dose omeprazole treatment combined with amoxicillin eradicates Helicobacter pylori. Eur J Gastroenterol Hepatol. 1992;4:697-702.
19. Collins R, Beattie S, Xia HX, O'Morain C. Short report: high-dose omeprazole and amoxycillin in the treatment of Helicobacter pylori-associated duodenal ulcer. Aliment Pharmacol Ther. 1993;7:313-5. (Pubitemid 23198306)
20. Fleischmann R, Demharter R, Barnert J, Fuger K, Wienbeck M, Busch R. Eradication of Helicobacter pylori in peptic ulcer disease with amoxycillin, 2.0 g, and omeprazole, 80 or 120 mg: a prospective randomized trial. Eur J Gastroenterol Hepatol. 1997;9(6):593-8. (Pubitemid 27267691)
21. Graham KS, Malaty H, El-Zimaity HM, Genta RM, Cole RA, Al-Assi MT, et al. Variability with omeprazole-amoxicillin combinations for treatment of Helicobacter pylori infection. Am J Gastroenterol. 1995;90:1415-8.
22. Labenz J, Stolte M, Blum AL, Jorias I, Leverkus F, Sollbohmer M, et al. Intragastric acidity as a predictor of the success of Helicobacter pylori eradication: a study in peptic ulcer patients with omeprazole and amoxicillin. Gut. 1995;37:39-43.
23. Labenz J, Ruhl GH, Bertrams J, Borsch G. Medium- and high-dose omeprazole plus amoxicillin for eradication of Helicobacter pylori in duodenal ulcer disease. Dig Dis Sci. 1994;39:1483-7. (Pubitemid 24246438)
24. Labenz J, Ruhl GH, Bertrams J, Borsch G. Medium- or high-dose omeprazole plus amoxicillin eradicates Helicobacter pylori in gastric ulcer disease. Am J Gastroenterol. 1994;89:726-30. (Pubitemid 24132055)
25. Labenz J, Leverkus F, Borsch G. Omeprazole plus amoxicillin for cure of Helicobacter pylori infection. Factors influencing the treatment success. Scand J Gastroenterol. 1994;29:1070-5. (Pubitemid 24374796)
26. Labenz J, Gyenes E, Ruhl GH, Börsch G. Short-term therapy with high dosage omeprazole and amoxicillin for Helicobacter pylori eradication. A pilot study. Med Klin. 1992;87:118-9.
27. Pommerien W, Schultze V, Braden B, Lembcke B, Wrangstadh M, Londong W. Dose-response of omeprazole combined with amoxycillin on duodenal ulcer healing and eradication of Helicobacter pylori. Aliment Pharmacol Ther. 1996;10(3):303-8. (Pubitemid 26173877)
28. Rokkas T, Mavrogeorgis A, Liatsos C, Rallis E, Kalogeropoulos N. Optimal dose of omeprazole in combination with amoxicillin in eradicating H. pylori and preventing relapses in duodenal ulcer patients. Hepatogastroenterology. 1995;42(6):842-6. (Pubitemid 26026442)
29. Sjostedt S, Sagar M, Lindberg G, Wikstrom B, Nord CE, Seensalu R. Prolonged and profound acid inhibition is crucial in Helicobacter pylori treatment with a proton pump inhibitor combined with amoxicillin. Scand J Gastroenterol. 1998;33(1):39-43. (Pubitemid 28114067)
30. van der Hulst RW, Weel JF, Verheul SB, Keller JJ, ten Kate FJ, van der Ende A, et al. Treatment of Helicobacter pylori infection with low or high dose omeprazole combined with amoxycillin and the effect of early retreatment. Aliment Pharmacol Ther. 1996;10:165-71. (Pubitemid 26117842)
31. Viiala CH, Windsor HM, Marshall BJ. Cure rate of high dose omeprazole and amoxicillin therapy for treatment-resistant Helicobacter pylori infection. J Gastroenterol Hepatol. 2005;20(4):663-4. (Pubitemid 40755291)
32. Harford W, Lanza F, Arora A, Graham D, Haber M, Weissfeld A, et al. Double-blind, multicenter evaluation of lansoprazole and amoxicillin dual therapy for the cure of Helicobacter pylori infection. Helicobacter. 1996;1(4):243-50. (Pubitemid 126671168)
33. Villoria A, Garcia P, Calvet X, Gisbert JP, Vergara M. Metaanalysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2008;28(7):868-77.
34. Sugimoto M, Graham DY. High-dose versus standard-dose PPI in triple therapy for Helicobacter pylori eradication. Nat Clin Pract Gastroenterol Hepatol. 2009;6(3):138-9.
35. Shirai N, Sugimoto M, Kodaira C, Nishino M, Ikuma M, Kajimura M, et al. Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy. Eur J Clin Pharmacol. 2007;63(8):743-9. (Pubitemid 47052044)
36. Furuta T, Ohashi K, Kamata T, Takashima M, Kosuge K, Kawasaki T, et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med. 1998;129(12):1027-30. (Pubitemid 29005826)
37. Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Nakagawa K, et al. Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. Pharmacogenetics. 2001;11(4):341-8. (Pubitemid 32537408)
38. Furuta T, Shirai N, Xiao F, Takashita M, Sugimoto M, Kajimura M, et al. High-dose rabeprazole/amoxicillin therapy as the sec-ond- line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003;50(54):2274-8. (Pubitemid 37468045)
39. Furuta T, Shirai N, Kodaira M, Sugimoto M, Nogaki A, Kuriyama S, et al. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther. 2007;81(4):521-8. (Pubitemid 46452299)
40. Sugimoto M, Furuta T, Shirai N, Kodaira C, Nishino M, Yamade M, et al. Treatment strategy to eradicate Helicobacter pylori infection: impact of pharmacogenomics-based acid inhibition regimen and alternative antibiotics. Expert Opin Pharmacother. 2007;8(16):2701-17. (Pubitemid 350193712)
41. Scott D, Weeks D, Melchers K, Sachs G. The life and death of Helicobacter pylori. Gut. 1998;43(Suppl 1):S56-60. (Pubitemid 28338114)
42. Scott DR, Marcus EA, Wen Y, Oh J, Sachs G. Gene expression in vivo shows that Helicobacter pylori colonizes an acidic niche on the gastric surface. Proc Natl Acad Sci USA. 2007;104(17):7235-40. (Pubitemid 47186038)
43. Gotoh A, Akamatsu T, Shimizu T, Shimodaira K, Kaneko T, Kiyosawa K, et al. Additive effect of pronase on the efficacy of eradication therapy against Helicobacter pylori. Helicobacter. 2002;7(3):183-91. (Pubitemid 34665836)
44. Furuta T, Ohashi K, Kosuge K, Zhao XJ, Takashima M, Kimura M, et al. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther. 1999;65(5):552-61. (Pubitemid 29237329)
45. Furuta T, Shirai N, Ohashi K, Ishizaki T. Therapeutic impact of CYP2C19 pharmacogenetics on proton pump inhibitor-based eradication therapy for Helicobacter pylori. Methods Find Exp Clin Pharmacol. 2003;25(2):131-43. (Pubitemid 36406973)
46. Schwab M, Schaeffeler E, Klotz U, Treiber G. CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori. Clin Pharmacol Ther. 2004;76(3):201-9. (Pubitemid 39221794)
47. Atherton JC, Hudson N, Kirk GE, Hawkey CK, Spiller RC. Amoxycillin capsules with omeprazole for the eradication of Helicobacter pylori. Assessment of the importance of antibiotic dose timing in relation to meals. Aliment Pharmacol Ther. 1994;8:495-8. (Pubitemid 24324486)
48. Atherton JC, Cullen DJ, Kirk GE, Hawkey CJ, Spiller RC. Enhanced eradication of Helicobacter pylori by pre- versus postprandial amoxycillin suspension with omeprazole: implications for antibiotic delivery. Aliment Pharmacol Ther. 1996;10(4):631-5. (Pubitemid 26254808)
49. Graham DY, Abudayyeh S, El-Zimaity HM, Hoffman J, Reddy R, Opekun AR. Sequential therapy using high-dose esomeprazole-amoxicillin followed by gatifloxacin for Helicobacter pylori infection. Aliment Pharmacol Ther. 2006;24(5):845-50.
50. de Boer WA, Thys JC, Borody TJ, Graham DY, O'Morain C, Tytgat GN. Proposal for use of a standard side effect scoring system in studies exploring Helicobacter pylori treatment regimens. Eur J Gastroenterol Hepatol. 1996;8(7):641-3. (Pubitemid 26241591)
51. Graham DY. Efficient identification and evaluation of effective Helicobacter pylori therapies. Clin Gastroenterol Hepatol. 2009;7(2):145-8.
52. Sugimoto M, Furuta T, Shirai N, Kodaira C, Nishino M, Ikuma M, et al. Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Helicobacter. 2007;12(4):317-23. (Pubitemid 47196333)
53. Lou HY, Chang CC, Sheu MT, Chen YC, Ho HO. Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism. Eur J Clin Pharmacol. 2009;65(1):55-64.
54. Klotz U. Proton pump inhibitors - their pharmacological impact on the clinical management of acid-related disorders. Arzneimittelforschung. 2009;59(6):271-82.
55. Julapalli VR, Graham DY. Appropriate use of intravenous proton pump inhibitors in the management of bleeding peptic ulcer. Dig Dis Sci. 2005;50(7):1185-93. (Pubitemid 41184741)
56. Tanimura H, Kawano S, Kubo M, Abe T, Goto M, Tanabe J, et al. Does Helicobacter pylori eradication depend on the period of amoxicillin treatment? A retrospective study. J Gastroenterol. 1998;33(1):23-6. (Pubitemid 28067770)